Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial

PURPOSE: This study aimed to establish the efficacy, safety, and immunogenicity equivalence of the proposed biosimilar CKD-701 with the reference ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD). PATIENTS AND METHODS: A total of 312 participants with a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Chang Ki, Oh, Jaeryung, Bae, Kunho, Park, Un Chul, Yu, Kyung-Sang, Yu, Hyeong Gon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662729/
https://www.ncbi.nlm.nih.gov/pubmed/36374913
http://dx.doi.org/10.1371/journal.pone.0275611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662729/
https://www.ncbi.nlm.nih.gov/pubmed/36374913
http://dx.doi.org/10.1371/journal.pone.0275611

Ejemplares similares